Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2004 May;59(5):387–395. doi: 10.1136/thx.2003.008730

Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study

M Miravitlles 1, M Ferrer 1, A Pont 1, R Zalacain 1, J Alvarez-Sala 1, F Masa 1, H Verea 1, C Murio 1, F Ros 1, R Vidal 1
PMCID: PMC1746989  PMID: 15115864

Abstract

Background: A study was undertaken to evaluate exacerbations and their impact on the health related quality of life (HRQL) of patients with chronic obstructive pulmonary disease (COPD).

Methods: A 2 year follow up study was performed in 336 patients with COPD of mean (SD) age 66 (8.2) years and mean (SD) forced expiratory volume in 1 second (FEV1) 33 (8)% predicted. Spirometric tests, questions regarding exacerbations of COPD, and HRQL measurements (St George's Respiratory Questionnaire (SGRQ) and SF-12 Health Survey) were conducted at 6 month intervals.

Results: A total of 1015 exacerbations were recorded, and 103 (30.7%) patients required at least one hospital admission during the study. After adjustment for baseline characteristics and season of assessment, frequent exacerbations had a negative effect on HRQL in patients with moderate COPD (FEV1 35–50% predicted); the change in SGRQ total score of moderate patients with ⩾3 exacerbations was almost two points per year greater (worse) than those with <3 exacerbations during the follow up (p = 0.042). For patients with severe COPD (FEV1 <35% predicted) exacerbations had no effect on HRQL. The change in SGRQ total score of patients admitted to hospital was almost 2 points per year greater (worse) than patients not admitted, but this effect failed to show statistical significance in any severity group. There was a significant and independent seasonal effect on HRQL since SGRQ total scores were, on average, 3 points better in measurements performed in spring/summer than in those measured in the winter (p<0.001).

Conclusions: Frequent exacerbations significantly impair HRQL of patients with moderate COPD. A significant and independent effect of seasonality was also observed.

Full Text

The Full Text of this article is available as a PDF (268.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaron Shawn D., Vandemheen Katherine L., Clinch Jennifer J., Ahuja Jan, Brison Robert J., Dickinson Garth, Hébert Paul C. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest. 2002 Mar;121(3):688–696. doi: 10.1378/chest.121.3.688. [DOI] [PubMed] [Google Scholar]
  2. Alonso J., Prieto L., Antó J. M. La versión española del SF-36 Health Survey (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados clínicos. Med Clin (Barc) 1995 May 27;104(20):771–776. [PubMed] [Google Scholar]
  3. Alvarez-Sala J., Cimas E., Masa J., Miravitlles M., Molina J., Naberan K., Simonet P., Viejo J., Grupo de Trabajo de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Sociedad Española de Medicina de Familia y Comunitaria (semFYC) Recomendaciones para la atención al paciente con enfermedad pulmonar obstructiva crónica. Arch Bronconeumol. 2001 Jul-Aug;37(7):269–278. doi: 10.1016/s0300-2896(01)75089-2. [DOI] [PubMed] [Google Scholar]
  4. Anthonisen N. R., Manfreda J., Warren C. P., Hershfield E. S., Harding G. K., Nelson N. A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987 Feb;106(2):196–204. doi: 10.7326/0003-4819-106-2-196. [DOI] [PubMed] [Google Scholar]
  5. Celli Bartolome R., Cote Claudia G., Marin Jose M., Casanova Ciro, Montes de Oca Maria, Mendez Reina A., Pinto Plata Victor, Cabral Howard J. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004 Mar 4;350(10):1005–1012. doi: 10.1056/NEJMoa021322. [DOI] [PubMed] [Google Scholar]
  6. Doll H., Grey-Amante P., Duprat-Lomon I., Sagnier P. P., Thate-Waschke I., Lorenz J., Rychlik R., Pfeil T. Quality of life in acute exacerbation of chronic bronchitis: results from a German population study. Respir Med. 2002 Jan;96(1):39–51. doi: 10.1053/rmed.2001.1208. [DOI] [PubMed] [Google Scholar]
  7. Ferrer M., Alonso J., Morera J., Marrades R. M., Khalaf A., Aguar M. C., Plaza V., Prieto L., Antó J. M. Chronic obstructive pulmonary disease stage and health-related quality of life. The Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med. 1997 Dec 15;127(12):1072–1079. doi: 10.7326/0003-4819-127-12-199712150-00003. [DOI] [PubMed] [Google Scholar]
  8. Ferrer M., Alonso J., Prieto L., Plaza V., Monsó E., Marrades R., Aguar M. C., Khalaf A., Antó J. M. Validity and reliability of the St George's Respiratory Questionnaire after adaptation to a different language and culture: the Spanish example. Eur Respir J. 1996 Jun;9(6):1160–1166. doi: 10.1183/09031936.96.09061160. [DOI] [PubMed] [Google Scholar]
  9. Ferrer M., Villasante C., Alonso J., Sobradillo V., Gabriel R., Vilagut G., Masa J. F., Viejo J. L., Jiménez-Ruiz C. A., Miravitlles M. Interpretation of quality of life scores from the St George's Respiratory Questionnaire. Eur Respir J. 2002 Mar;19(3):405–413. doi: 10.1183/09031936.02.00213202. [DOI] [PubMed] [Google Scholar]
  10. Jiménez-Ruiz C. A., Sobradillo V., Gabriel R., Viejo J. L., Masa J. F., Miravitlles M., Villasante C., Fernández-Fau L. Síntomas respiratorios y diagnóstico de EPOC en fumadores de distintas labores de tabaco. Resultados del estudio IBERPOC. Arch Bronconeumol. 2002 Nov;38(11):530–535. doi: 10.1016/s0300-2896(02)75282-4. [DOI] [PubMed] [Google Scholar]
  11. Jones P. W., Bosh T. K. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997 Apr;155(4):1283–1289. doi: 10.1164/ajrccm.155.4.9105068. [DOI] [PubMed] [Google Scholar]
  12. Jones P. W. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002 Mar;19(3):398–404. doi: 10.1183/09031936.02.00063702. [DOI] [PubMed] [Google Scholar]
  13. Jones P. W., Quirk F. H., Baveystock C. M., Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992 Jun;145(6):1321–1327. doi: 10.1164/ajrccm/145.6.1321. [DOI] [PubMed] [Google Scholar]
  14. Kanner R. E., Anthonisen N. R., Connett J. E., Lung Health Study Research Group Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001 Aug 1;164(3):358–364. doi: 10.1164/ajrccm.164.3.2010017. [DOI] [PubMed] [Google Scholar]
  15. Koopmans Marion, Wilbrink Berry, Conyn Marina, Natrop Gerard, van der Nat Hans, Vennema Harry, Meijer Adam, van Steenbergen Jim, Fouchier Ron, Osterhaus Albert. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet. 2004 Feb 21;363(9409):587–593. doi: 10.1016/S0140-6736(04)15589-X. [DOI] [PubMed] [Google Scholar]
  16. Miravitlles M., Alvarez-Sala J. L., Lamarca R., Ferrer M., Masa F., Verea H., Zalacain R., Murio C., Ros F., IMPAC Study Group Treatment and quality of life in patients with chronic obstructive pulmonary disease. Qual Life Res. 2002 Jun;11(4):329–338. doi: 10.1023/a:1015520110663. [DOI] [PubMed] [Google Scholar]
  17. Miravitlles M., Guerrero T., Mayordomo C., Sánchez-Agudo L., Nicolau F., Segú J. L. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration. 2000;67(5):495–501. doi: 10.1159/000067462. [DOI] [PubMed] [Google Scholar]
  18. Miravitlles M., Mayordomo C., Artés M., Sánchez-Agudo L., Nicolau F., Segú J. L. Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitación Obstructiva al Flujo aEreo. Respir Med. 1999 Mar;93(3):173–179. doi: 10.1016/s0954-6111(99)90004-5. [DOI] [PubMed] [Google Scholar]
  19. Miravitlles M., Murio C., Guerrero T. Factors associated with relapse after ambulatory treatment of acute exacerbations of chronic bronchitis. DAFNE Study Group. Eur Respir J. 2001 May;17(5):928–933. doi: 10.1183/09031936.01.17509280. [DOI] [PubMed] [Google Scholar]
  20. Miravitlles Marc, Murio Cristina, Guerrero Tina, Gisbert Ramon, DAFNE Study Group. Decisiones sobre Antibioticoterapia y Farmacoeconomía en la EPOC Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002 May;121(5):1449–1455. doi: 10.1378/chest.121.5.1449. [DOI] [PubMed] [Google Scholar]
  21. Miravitlles Marc, Zalacain Rafael, Murio Cristina, Ferrer Montserrat, Alvarez-Sala José L., Masa Juan F., Verea Héctor, Ros Fernando, Vidal Rafael, IMPAC Study Group (see page 448) Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials : results of a two-year study. Clin Drug Investig. 2003;23(7):439–450. doi: 10.2165/00044011-200323070-00003. [DOI] [PubMed] [Google Scholar]
  22. Osman I. M., Godden D. J., Friend J. A., Legge J. S., Douglas J. G. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax. 1997 Jan;52(1):67–71. doi: 10.1136/thx.52.1.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pauwels R. A., Buist A. S., Calverley P. M., Jenkins C. R., Hurd S. S., GOLD Scientific Committee Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001 Apr;163(5):1256–1276. doi: 10.1164/ajrccm.163.5.2101039. [DOI] [PubMed] [Google Scholar]
  24. Peña V. S., Miravitlles M., Gabriel R., Jiménez-Ruiz C. A., Villasante C., Masa J. F., Viejo J. L., Fernández-Fau L. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest. 2000 Oct;118(4):981–989. doi: 10.1378/chest.118.4.981. [DOI] [PubMed] [Google Scholar]
  25. Seemungal T. A., Donaldson G. C., Bhowmik A., Jeffries D. J., Wedzicha J. A. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 May;161(5):1608–1613. doi: 10.1164/ajrccm.161.5.9908022. [DOI] [PubMed] [Google Scholar]
  26. Seemungal T. A., Donaldson G. C., Paul E. A., Bestall J. C., Jeffries D. J., Wedzicha J. A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1418–1422. doi: 10.1164/ajrccm.157.5.9709032. [DOI] [PubMed] [Google Scholar]
  27. Spencer S., Calverley P. M., Sherwood Burge P., Jones P. W., ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Jan;163(1):122–128. doi: 10.1164/ajrccm.163.1.2005009. [DOI] [PubMed] [Google Scholar]
  28. Spencer S., Jones P. W., GLOBE Study Group Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003 Jul;58(7):589–593. doi: 10.1136/thorax.58.7.589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Susilo Rudy, Korting Hans C., Strauss Uwe Phillip, Sertaconazole Study Group Dermatomycoses of the glabrous skin : a double-blind, randomised, comparative trial of sertaconazole 2% cream once daily versus vehicle. Clin Drug Investig. 2003;23(6):387–394. doi: 10.2165/00044011-200323060-00002. [DOI] [PubMed] [Google Scholar]
  30. Tsukino M., Nishimura K., Ikeda A., Koyama H., Mishima M., Izumi T. Physiologic factors that determine the health-related quality of life in patients with COPD. Chest. 1996 Oct;110(4):896–903. doi: 10.1378/chest.110.4.896. [DOI] [PubMed] [Google Scholar]
  31. Vincken W., van Noord J. A., Greefhorst A. P. M., Bantje Th A., Kesten S., Korducki L., Cornelissen P. J. G., Dutch/Belgian Tiotropium Study Group Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002 Feb;19(2):209–216. doi: 10.1183/09031936.02.00238702. [DOI] [PubMed] [Google Scholar]
  32. Ware J., Jr, Kosinski M., Keller S. D. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996 Mar;34(3):220–233. doi: 10.1097/00005650-199603000-00003. [DOI] [PubMed] [Google Scholar]
  33. ZuWallack R. L., Mahler D. A., Reilly D., Church N., Emmett A., Rickard K., Knobil K. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest. 2001 Jun;119(6):1661–1670. doi: 10.1378/chest.119.6.1661. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES